Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
It wasn’t too long ago that Ilan Ganot was a J.P. Morgan banker. Then his son, Eytani, was diagnosed with Duchenne muscular dystrophy, and he ended up the head of a... Read more »
With new data released this evening, Vertex Pharmaceuticals is closer to bringing its third cystic fibrosis treatment to market, which would mean the company’s product line could potentially treat upwards of... Read more »
[Updated, 5:30 pm E.T., see below] PTC Therapeutics inherited a drug pricing controversy last week when it paid $140 million for deflazacort (Emflaza), a steroid used to treat Duchenne... Read more »
Akashi Therapeutics has been cleared by the FDA to resume testing an experimental Duchenne muscular dystrophy drug roughly a year after a patient taking the treatment died in a clinical trial.... Read more »
It’s not an understatement to say 2017 is a crucial year for the growth of the life sciences industry in New York.
Cerulean Pharma may have been able to survive one brush with death, but the second has proven fatal. Today, the Waltham, MA, company announced plans to merge with a privately held... Read more »
It’s tough to stand out in the cancer immunotherapy crowd, where a slew of companies are testing a variety of drug combinations and new methods to help boost responses to existing... Read more »
Stung by slow sales of its next-generation anti-cholesterol drug, Amgen hopes new clinical data, released this morning, will spur doctors to boost prescriptions and—perhaps more important—drive insurers to loosen their restrictions.... Read more »
Slowly but surely, CRISPR-Cas9 gene editing treatments are working their way towards human clinical testing, spurring more large pharmaceutical companies to get in on their future. The latest today is Allergan,... Read more »
[Updated 3/12/17 with more comments, see below] The Trump administration has nominated Scott Gottlieb to be the new commissioner of the FDA, a selection that had the life sciences... Read more »
We’ll start the roundup in Washington DC. The repeal of the Affordable Care Act, also known as Obamacare, began on the first day of the Trump administration. This week, the “replace”... Read more »
Boston biotech veteran Deborah Dunsire is back running another life sciences company—but for the first time, a fledgling startup. The former head of Millennium Pharmaceuticals is now president and CEO of... Read more »
Concert Pharmaceuticals has been plugging away with an experimental cystic fibrosis drug that, if successful, might someday pose a threat to Vertex Pharmaceuticals. So rather than wait to find out, Vertex... Read more »
There may be a new standard of care coming for a large portion of women with breast cancer who have had surgery to remove their tumors. A drug from Roche’s South... Read more »
Last month, Grail publicly spread word of intentions to raise more than $1 billion in an ambitious quest to develop a blood test that can diagnose and detect cancer at its... Read more »
Two newly approved drugs slow the progression of the rare and deadly Duchenne muscular dystrophy, but nothing on the market actually reverses the march of the disease. An emerging group of... Read more »
A year after selling his latest biotech startup—the second since 2012—Michael Gilman is back. He emerged today as chairman and CEO of a two-year-old startup named Arrakis Therapeutics, which aims to... Read more »
Harvard University chemical biologist Greg Verdine has been learning how to start and run biotech companies for almost two decades. He’s been a scientific co-founder of ten startups, worked at three... Read more »
PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known... Read more »
© 2007-2017, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.